Equity Research, Broker Reports, and media content on Shandong Weigao Group Medical Polymer Co. Ltd. Unsponsored ADR Class H

  • Access the latest forecasts, broker valuations, multiples, and video content from the city about Shandong Weigao Group Medical Polymer Co. Ltd. Unsponsored ADR Class H
  • See live updates from analysts, company announcements, and other news in a personalised/single dashboard

Shandong Weigao Group Medical Polymer Co. Ltd. Unsponsored ADR Class H

Company Profile

Research, Charts & Company Announcements

Research Tree provides access to ongoing research coverage, media content and regulatory news on Shandong Weigao Group Medical Polymer Co. Ltd. Unsponsored ADR Class H. We currently have 0 research reports from 0 professional analysts.

  • Open: N/A
  • Range Today: N/A
  • 52 Week: 0.00/0.00
  • Daily Volume: N/A
  • Daily Liquidity: 0.0%
  • # Shares: 0m
  • Market Cap: 0m
  • Latest PE (hist):
  • Div Yield:

Latest News/RNS

(more news)
Date Source Announcement
Get free RNS email alerts

  • Frequency of research reports

     

  • Research reports on

    Shandong Weigao Group Medical Polymer Co. Ltd. Unsponsored ADR Class H

  • Providers covering

    Shandong Weigao Group Medical Polymer Co. Ltd. Unsponsored ADR Class H

  • 29 Jul 21
Underlying business recovers, full-year earnings outlook reiterated

In its first Litmus test after an ‘ambitious’ CMD in June 2021, the British giant has put up a decent show. The group witnessed recovery in the base business, particularly in vaccines which benefited from the sales of COVID-19 vaccine adjuvant. While the near term continues be tricky due to resurfacing COVID-19 concerns, encouraging trends on the COVID-19 vaccine / treatment front and growing HIV and oncology prowess should calm the nerves.

Companies: GlaxoSmithKline plc
  • 03 Aug 21
Trading Update

Cambridge Cognition has released a very encouraging H1 update which was well ahead of our forecasts and we have upgraded our FY21 revenue estimate by +19%. Order intake in the period leapt +74% to £8.6m (H1 2020: £4.9m), including £6.4m of previously-announced large orders, including two very significant wins totalling £3.6m. H1 revenues rose +50% to £4.5m, well ahead of DCe £3.8m and the group delivered Adjusted EBITDA of £0.2m vs DCe breakeven. Customer prepayments from contracts resulted in a

Companies: Cambridge Cognition Holdings Plc
  • 28 Jul 21
ANGLE - Pharma services contract with new customer

ANGLE announced its second pharma services contract with an undisclosed drug development company, using Parsortix firstly to develop two custom CTC assays to look at biomarkers of DNA damage repair, for which it will be paid c.$0.4m and, secondly, if successful, to use these validated assays for longitudinal analysis in a subsequent clinical trial planned to start in H2 2022. The revenue from the first phase of the contract is expected to be recognised over a 12-month period. ANGLE also confirme

Companies: ANGLE plc
  • 02 Aug 21
Healthy sales growth blotted by near-term margin pressure

In Q2, Astra reported strong sales growth momentum, (again) driven by a strong showing in oncology, diabetes drug Farxiga and COVID-19 vaccine sales. Although there were some issues in R&I and CVRM. More importantly, at cost vaccine sales and mandatory VBP discounts in China weighed on profitability. While the profitability strain can sustain in H2 as well, one should find confidence from the robust potential of core pharma offerings and the addition of high-growth and excellent-margin Alexion,

Companies: AstraZeneca PLC
  • 03 Aug 21
Cambridge Cognition - Strong six-month trading update, record order book & upgrades

A positive trading update for H1 2021 prompts full-year upgrades to forecasts and provides the basis for the introduction of FY 2022 forecasts. H1 2021 sales orders increased 74% to £8.6m; up from £4.9m in H1 2020, with a 50% increase in revenues and a £0.5m increase in adjusted EBITDA to £0.2m. A record contracted order backlog (up 36% or £4.0m from 31 December 2020 to £15.2m), which contains several large contracts with revenues to be recognised over up to six years, provides improved long-ter

Companies: Cambridge Cognition Holdings Plc
  • 29 Jul 21
Q2 21: Marginal beat not good enough

Smith & Nephew reported consensus beating Q2 21 sales growth of 40.3%, thanks to a strong recovery in Orthopaedics (+43.4%) and ‘sports medicine & ENT’ (+50.9%). Regionally, growth was driven by the established markets (+46.8%). For H1, revenue growth came in at 27.8% with a trading margin of 17.6% (+920bps, 40bps ahead of consensus). Guidance of 10%-13% top-line growth and an 18%-19% trading margin was re-iterated. Following the broadly in-line performance, we do not expect any significant ch

Companies: Smith & Nephew PLC
  • 01 Jul 21
It's coming home, it's coming home - inflation's coming home!

What a difference a year makes - 12 months ago, the focus, quite understandably, was on the course of the pandemic and the lifting of the Lockdown (1) measures. For investors, it was the sustainability of the rally in markets seen since March 2020. Today, while we are still thinking about the lifting of lockdown measures, we are also concerned about two “old favourites” from previous decades. Inflation and the parlous state of public finances. The BoE has said that although CPI inflation rose to

Companies: AEMC BVC BAG BRSD BWNG CBOX CEG CTG CLG CML CRPR DNK EML ESC FAR FA/ GPH INSE MTW MOTR MMAG NRR NESF NMCN NSF OTMP OBD SAVE SCS STVG SNX SYS TMG TGL VLS VOG WYN

  • 29 Jul 21
Doctor Care Anywhere Group - On track to meet 100% growth target

Doctor Care Anywhere Group's (DOC) Q221 update highlights that underlying revenue has continued to increase, driven by its expanding internet hospital and subsequent growth in diagnostic referrals. Management remains confident that FY21 revenue will be at least 100% above FY20 levels, implying a total revenue of at least £23.2m. Its balance sheet remains strong with net cash of £31.5m. The expected Q421 launch of its digitally integrated virtual and in-person primary care service with Nuffield H

Companies: Doctor Care Anywhere Group PLC Shs Chess Depository Interests Repr 1 sh
  • 31 Mar 17
N+1 Singer - T2 Trend spotting - Strategy update

In our second edition of “Trend spotting” we note how in the last three weeks the defensive rotation trend has gathered pace and further evidence has emerged of the “relative fading” in the UK economy. However we now see early signs of the “risk on” trend starting to reassert itself in equity markets and we look at small cap laggards plus European exposure as ways to play this.

Companies: GNS REDD SPH TRI XAR BOY VCT GHH CHH DPH INS HILS RPS LWB EKF UDG SYNT MYSL BCA JUP KMK

  • 03 Oct 19
Small Cap Feast


Companies: ABDP IHC BIRD JWNG MACP RBD FARN MIND EQLS CHRT

  • 11 Aug 20
Resilient performance leads to upgrades

SDL delivered a better than forecast H1, outperforming sales and AOP estimates. Revenues moderated by just 1% to £180.7m, with AOP up 1% to £16.3m. Increased demand from strongly performing verticals (Online Retail, Technology) has offset declining volumes from CV19 impacted sectors (Leisure, Travel, Automotive). KPIs continue to move in the right direction, with ARCV rising 7% y/y, and Linguistic Productive Utilisation stable at 67%. The Group delivered 60 new technology customer wins in H1, an

Companies: RWS Holdings plc
  • 23 Sep 20
Interim results: Re-introducing FY2020 forecasts with interim dividend of 2.8p

Warpaint’s interim results for FY2020 reflect the impact from Covid-19, with revenues of £13.5m, down 29% year-on-year (yoy) and adjusted profits from operations of £0.4m. Importantly, net cash has improved to £3.8m, up from £2.7m at the end of December 2019. We highlight the outlook statement, in particular, the recovering revenue in H2, the proposed interim dividend of 1.5p, together with an additional 1.3p to reflect no final dividend was paid for 2019, as signs of confidence from the Board.

Companies: Warpaint London PLC
  • 18 Jan 21
Better Q4 than expected + distribution extension

Q4 trading has led sales to guidance being raised 8%. This has been driven by better than expected UK sales, incl. success with new customers like Wilko/Tesco. Some of the benefit is offset by a non-cash FX debit, but it still leads to an upgrade and higher net cash. As a result of successful trials in Tesco Express, W7 is also being rolled out to 469 more stores. This, and previously announced distribution gains, bodes well for incremental sales/PBT in 2021, and underlines the appeal of its val

Companies: Warpaint London PLC
  • 04 Feb 21
FY20 & H1-21 results released

With the audit process having been further complicated by the impact of the pandemic, ECO’s delayed results for the year ending Mar-20 and the half year ending Sep-20 have now been published. In headline terms, they are both very much in line with expectations. As previously discussed, trading suffered in H1-20 as the African Swine Fever outbreak in key market China impacted on demand. H2 was significantly stronger (60% of FY20 revenues) and that momentum has continued into FY21, with two signif

Companies: ECO Animal Health Group plc
  • 16 Feb 21
Small Cap Feast

AMTE Power, a developer and manufacturer of lithium-ion battery cells for specialist markets, announced its intention to seek admission to trading on AIM. Admission is expected to take place during March 2021. The Company intends to raise approximately £7 million by way of a placing of new ordinary shares in the capital of the Company. Timing TBC. Samarkand Group Limited, the cross-border eCommerce technology and retail group opening up the world's largest market for brands and retailers, intend

Companies: SAR PAF PTRO NEXS TYM BOD CLX FAB ODX DUKE